Drug Approval | December 03, 2025
LENZ Therapeutics, Lotus Pharmaceutical submit NDA for presbyopia treatment in Korea
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Now a test that offers new precision in prostate cancer detection
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd
Subscribe To Our Newsletter & Stay Updated
